Thelansis’s “Small Cell Lung Cancer (SCLC) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.
Small cell lung cancer (SCLC) is an aggressive, high-grade neuroendocrine carcinoma of the lung characterised by rapid doubling time, early metastatic dissemination, and initial chemosensitivity invariably followed by acquired resistance and relapse, with tobacco smoking as the overwhelmingly dominant aetiological driver. Genomic hallmarks include near-universal biallelic inactivation of TP53 and RB1, alongside amplification of MYC family oncogenes, producing a highly proliferative tumour with limited targetable driver mutations and profound immunosuppressive microenvironment. Disease is staged as limited, confined to one hemithorax within a tolerable radiotherapy field, or extensive, representing the majority at diagnosis. Patients present with rapidly progressive cough, dyspnoea, haemoptysis, superior vena cava syndrome, and paraneoplastic syndromes including SIADH, Lambert-Eaton myasthenic syndrome, and encephalitis. Diagnosis integrates CT and PET staging, tissue biopsy confirming neuroendocrine morphology, and paraneoplastic antibody assessment. Atezolizumab or durvalumab combined with platinum-etoposide chemotherapy constitutes the established frontline standard for extensive-stage SCLC, delivering modest but meaningful survival improvement over chemotherapy alone. Concurrent chemoradiation with prophylactic cranial irradiation or MRI surveillance addresses limited-stage disease. Lurbinectedin is approved for platinum-refractory relapsed disease, while topotecan retains utility in selected patients. Tarlatamab, a first-in-class DLL3-targeted bispecific T-cell engager, represents a landmark therapeutic advance demonstrating durable responses in heavily pretreated relapsed SCLC, establishing a transformative new treatment option. Prognosis remains poor with five-year survival below 7%; multidisciplinary management, early palliative integration, and patient-centred supportive care are indispensable to optimising quality of life and survival outcomes.
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
*Survey is customized based on client requirements
1. Key Findings and Analyst Commentary
2. Competitive Landscape
3. Product Attribute Analysis
4. Primary Market Research
5. Unmet Need and TPP Analysis
6. Regulatory and Reimbursement Environments (by country and payer insights)
7. Appendix (e.g., bibliography, methodology)
No snapshots available.
That depends on the file type you choose: the Excel epidemiology model, the Excel market forecast model with dashboard, and the full analyst report in PowerPoint with a PDF version.
Within 48 to 72 hours of purchase.
Yes. Choose EU5, G7 or G8, or pick individual markets in the panel.
Yes. Request a free sample to preview the scope and sample pages.
Yes. The forecast model is customizable, and our analysts can tailor the scope to your questions.
Yes. Inquire for bundle discounted pricing and we will send you exclusive pricing for the reports you need.
Choose the file type you want to purchase or request.
No file type found.
Select markets to include.
No markets match your search.
Not sure which report fits your question? Our team will point you to the right one.
Tell us what you are looking for and we will tailor the research to your indication, markets and questions.
Prefer to talk it through? Email clientsupport@thelansis.com
You asked for for covering . We will reply to .
Fill in your details and our expert consultants will get in touch with you.
Get a sneak peek at the latest Small Cell Lung Cancer (SCLC) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026 report
Our team will get in touch with you shortly about the Small Cell Lung Cancer (SCLC) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026 report.